XYLT1 and systemic sclerosis: Increased serum XT activity and/or cellular XYLT1 expression have been identified as biochemical markers for assessing fibrotic remodeling processes, such as the cytokine-mediated fibroblasts-to-myofibroblasts transition in SSc [21,27,28,45].